News und Analysen
EQS-News: Formycon confirms full-year guidance following business development in line with plan – working capital raised
EQS-News: Formycon confirms full-year guidance following business development in line with plan – working capital raised
EQS-News: Eckert & Ziegler: Further Increase in Earnings in the First Half of 2025
EQS-News: Eckert & Ziegler: Further Increase in Earnings in the First Half of 2025
EQS-News: Eckert & Ziegler: Implementation of the Share Split by Issuing Bonus Shares to Be Effective on 15 August 2025
EQS-News: Eckert & Ziegler: Implementation of the Share Split by Issuing Bonus Shares to Be Effective on 15 August 2025
EQS-News: MEDICLIN reports positive interim results for the first half of 2025
EQS-News: MEDICLIN reports positive interim results for the first half of 2025
EQS-News: Formycon invites to conference call on 2025 half-year results and announces participation in international investor conferences in the 3rd quarter of 2025
EQS-News: Formycon invites to conference call on 2025 half-year results and announces participation in international investor conferences in the 3rd quarter of 2025
EQS-News: Eckert & Ziegler Selected as US Manufacturer for Archeus’ Next-Generation Radiopharmaceutical ART-101
EQS-News: Eckert & Ziegler Selected as US Manufacturer for Archeus’ Next-Generation Radiopharmaceutical ART-101
EQS-News: Eckert & Ziegler: Capital Increase Entered in the Commercial Register. Share Split in Preparation.
EQS-News: Eckert & Ziegler: Capital Increase Entered in the Commercial Register. Share Split in Preparation.
EQS-News: Experienced biotechnology expert joins the Supervisory Board of BRAIN Biotech AG
EQS-News: Experienced biotechnology expert joins the Supervisory Board of BRAIN Biotech AG
EQS-News: Eckert & Ziegler: Outstanding Training Quality Once Again Awarded
EQS-News: Eckert & Ziegler: Outstanding Training Quality Once Again Awarded
EQS-News: Heidelberg Pharma Reports on First Half-Year 2025 and the Positive Course of Business
EQS-News: Heidelberg Pharma Reports on First Half-Year 2025 and the Positive Course of Business
EQS-News: Formycon successfully completes patient enrollment for the clinical development of its Keytruda® biosimilar candidate FYB206
EQS-News: Formycon successfully completes patient enrollment for the clinical development of its Keytruda® biosimilar candidate FYB206
EQS-News: Bio Usawa becomes partner for the commercialization of FYB201/ BioUcenta™ (ranibizumab) across Sub-Saharan Africa
EQS-News: Bio Usawa becomes partner for the commercialization of FYB201/ BioUcenta™ (ranibizumab) across Sub-Saharan Africa
EQS-News: Formycon increases bond volume following oversubscription – Bond 2025/2029 with a volume of EUR 70 million successfully and entirely placed
EQS-News: Formycon increases bond volume following oversubscription – Bond 2025/2029 with a volume of EUR 70 million successfully and entirely placed
EQS-Adhoc: Formycon successfully places an EUR 70 million senior unsecured floating rate bond
EQS-Adhoc: Formycon successfully places an EUR 70 million senior unsecured floating rate bond
EQS-News: Teva becomes secondary commercialization partner for Formycon's Stelara® biosimilar FYB202 (ustekinumab) under the brand name Fymskina® in Germany
EQS-News: Teva becomes secondary commercialization partner for Formycon's Stelara® biosimilar FYB202 (ustekinumab) under the brand name Fymskina® in Germany
EQS-News: U.S. biosimilar specialist Valorum Biologics LLC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/AHZANTIVE® (aflibercept-mrbb) in the United States and Canada
EQS-News: U.S. biosimilar specialist Valorum Biologics LLC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/AHZANTIVE® (aflibercept-mrbb) in the United States and Canada
EQS-News: Strong demand for Formycon 2025/2029 Bond leads to early closing of subscription period
EQS-News: Strong demand for Formycon 2025/2029 Bond leads to early closing of subscription period
EQS-News: Formycon bond 2025/2029: Public subscription now also possible via Deutsche Börse
EQS-News: Formycon bond 2025/2029: Public subscription now also possible via Deutsche Börse
EQS-News: Ordinary Annual General Meeting of Formycon AG approves all proposed resolutions by large majorities
EQS-News: Ordinary Annual General Meeting of Formycon AG approves all proposed resolutions by large majorities
EQS-News: Annual General Meeting of Eckert & Ziegler SE Approves Dividend of EUR 0.50
EQS-News: Annual General Meeting of Eckert & Ziegler SE Approves Dividend of EUR 0.50
EQS-News: Formycon AG: Subscription period for 2025/2029 corporate bond has started
EQS-News: Formycon AG: Subscription period for 2025/2029 corporate bond has started
EQS-News: Formycon plans public corporate bond issuance to support next growth phase within attractive Biosimilar markets
EQS-News: Formycon plans public corporate bond issuance to support next growth phase within attractive Biosimilar markets
EQS-Adhoc: Formycon plans to issue a public senior unsecured floating rate bond with target volume of EUR 50 million to support further company growth
EQS-Adhoc: Formycon plans to issue a public senior unsecured floating rate bond with target volume of EUR 50 million to support further company growth
EQS-News: MPH Health Care AG publishes figures for the first quarter of 2025:
EQS-News: MPH Health Care AG publishes figures for the first quarter of 2025:
EQS-News: Eckert & Ziegler: Illuccix® PSMA-PET Imaging Agent Receives Approval in Germany
EQS-News: Eckert & Ziegler: Illuccix® PSMA-PET Imaging Agent Receives Approval in Germany